Evaluation of potential of targeted sequencing through mutational signature simulation.

<h4>Background</h4>Targeted sequencing is critical in cancer diagnosis, treatment selection, and monitoring. However, the effectiveness of these methods for reflecting whole-exome sequencing (WES)-level mutational signatures remains unclear. Therefore, we addressed this issue through sim...

Full description

Saved in:
Bibliographic Details
Main Authors: Keisuke Kodama, Yiwei Ling, Hiroshi Ichikawa, Toshifumi Wakai, Shujiro Okuda
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0326071
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849424639612157952
author Keisuke Kodama
Yiwei Ling
Hiroshi Ichikawa
Toshifumi Wakai
Shujiro Okuda
author_facet Keisuke Kodama
Yiwei Ling
Hiroshi Ichikawa
Toshifumi Wakai
Shujiro Okuda
author_sort Keisuke Kodama
collection DOAJ
description <h4>Background</h4>Targeted sequencing is critical in cancer diagnosis, treatment selection, and monitoring. However, the effectiveness of these methods for reflecting whole-exome sequencing (WES)-level mutational signatures remains unclear. Therefore, we addressed this issue through simulation-based analysis to clarify how well targeted sequencing can reproduce WES-level mutational signatures.<h4>Methods</h4>We compared the correlation and similarity of mutational signatures between whole-exome sequencing-level mutation data and downsampled data for gene sets targeted by each sequencing method in 13 cancer types. Additionally, a similarity analysis of the mutational signatures was conducted using randomly downsampled data.<h4>Results</h4>The comparison between whole-exome sequencing and targeted sequencing showed a low correlation based on Pearson's correlation coefficient but a high similarity based on the Dice similarity index. As a result of the downsampling of data with cancer-related genes and whole genes to evaluate similarity, the cancer-related gene random set showed high similarity when 200-400 genes were selected. However, the whole-genome random set required 2-3 times as many genes as the cancer-related gene random set to show high similarity. Among cancer types, colorectal and lung cancers demonstrated high similarity with fewer downsampled genes, whereas breast and prostate cancers required more downsampled genes to achieve high similarity.<h4>Conclusion</h4>This study demonstrated that current clinically used targeted sequencing methods can reflect whole-exome sequencing-level mutational signatures. This suggests that considering the cancer type and average number of gene mutations in each patient when selecting targeted sequencing methods can lead to more effective treatment choices.
format Article
id doaj-art-e1301622dc474f069d2be38f3924ab85
institution Kabale University
issn 1932-6203
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-e1301622dc474f069d2be38f3924ab852025-08-20T03:30:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01206e032607110.1371/journal.pone.0326071Evaluation of potential of targeted sequencing through mutational signature simulation.Keisuke KodamaYiwei LingHiroshi IchikawaToshifumi WakaiShujiro Okuda<h4>Background</h4>Targeted sequencing is critical in cancer diagnosis, treatment selection, and monitoring. However, the effectiveness of these methods for reflecting whole-exome sequencing (WES)-level mutational signatures remains unclear. Therefore, we addressed this issue through simulation-based analysis to clarify how well targeted sequencing can reproduce WES-level mutational signatures.<h4>Methods</h4>We compared the correlation and similarity of mutational signatures between whole-exome sequencing-level mutation data and downsampled data for gene sets targeted by each sequencing method in 13 cancer types. Additionally, a similarity analysis of the mutational signatures was conducted using randomly downsampled data.<h4>Results</h4>The comparison between whole-exome sequencing and targeted sequencing showed a low correlation based on Pearson's correlation coefficient but a high similarity based on the Dice similarity index. As a result of the downsampling of data with cancer-related genes and whole genes to evaluate similarity, the cancer-related gene random set showed high similarity when 200-400 genes were selected. However, the whole-genome random set required 2-3 times as many genes as the cancer-related gene random set to show high similarity. Among cancer types, colorectal and lung cancers demonstrated high similarity with fewer downsampled genes, whereas breast and prostate cancers required more downsampled genes to achieve high similarity.<h4>Conclusion</h4>This study demonstrated that current clinically used targeted sequencing methods can reflect whole-exome sequencing-level mutational signatures. This suggests that considering the cancer type and average number of gene mutations in each patient when selecting targeted sequencing methods can lead to more effective treatment choices.https://doi.org/10.1371/journal.pone.0326071
spellingShingle Keisuke Kodama
Yiwei Ling
Hiroshi Ichikawa
Toshifumi Wakai
Shujiro Okuda
Evaluation of potential of targeted sequencing through mutational signature simulation.
PLoS ONE
title Evaluation of potential of targeted sequencing through mutational signature simulation.
title_full Evaluation of potential of targeted sequencing through mutational signature simulation.
title_fullStr Evaluation of potential of targeted sequencing through mutational signature simulation.
title_full_unstemmed Evaluation of potential of targeted sequencing through mutational signature simulation.
title_short Evaluation of potential of targeted sequencing through mutational signature simulation.
title_sort evaluation of potential of targeted sequencing through mutational signature simulation
url https://doi.org/10.1371/journal.pone.0326071
work_keys_str_mv AT keisukekodama evaluationofpotentialoftargetedsequencingthroughmutationalsignaturesimulation
AT yiweiling evaluationofpotentialoftargetedsequencingthroughmutationalsignaturesimulation
AT hiroshiichikawa evaluationofpotentialoftargetedsequencingthroughmutationalsignaturesimulation
AT toshifumiwakai evaluationofpotentialoftargetedsequencingthroughmutationalsignaturesimulation
AT shujirookuda evaluationofpotentialoftargetedsequencingthroughmutationalsignaturesimulation